• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie 3/2007

Zastosowanie selektywnych α2-mimetyków w terapii jaskry

Selective α2-mimetics Use in Glaucoma Therapy

Magdalena Pilas-Pomykalska, Anna Wyrwicka, Joanna Juszczyk, Dorota Tomaszkiewicz-Mondry, Janusz Czajkowski

Klinika Okulistyki Instytutu "Centrum Zdrowia Matki Polki" w Łodzi Kierownik: prof. dr hab. n. med. Janusz Czajkowski

Summary: The authors present the application of high selective α2-mimetics in glaucoma therapy. 0.2% briminidine tartrate (Alphagan) belongs to 3rd generation of α2agonists with the highest selectivity to α2receptors. Brimonidine reduces IOP in two ways: by aqueous humor production reduction and uveoscleral outflow increase. Alphagan is useful as monotherapy with efficacy similar to non-selective β-blockers or as adjunctive treatment. The authors discuss its indications, efficacy, safety and side effects in glaucoma treatment.

Keywords: α2-mimetics, brimonidine, glaucoma treatment.

powrót